Inception Sciences Canada Inc

Clearmind Medicine is a Vancouver-based biotechnology company focused on developing innovative psychedelic treatments for addiction and mental health disorders, particularly targeting alcohol use disorder. Their lead treatment candidate, MEAI, is designed to provide a euphoric experience similar to alcohol while reducing the desire for excessive consumption. With a robust patent portfolio and a team experienced in clinical trials and healthcare, Clearmind aims to address critical societal issues related to substance abuse and mental health, which impose significant economic costs. The company's research underscores its commitment to changing lives for millions who struggle with binge behaviors and related conditions. Generated from the website

Braxia Scientific Corp, based in Vancouver, BC, is a pioneering medical research company focused on innovative treatments for depression, suicidality, and related mental health conditions through ketamine and psilocybin therapies. With a commitment to best practices in clinical care, the company operates multiple clinics across North America and is dedicated to advancing psychedelic medicine for improved mental wellness. Led by a top-ranked researcher in depression, Braxia Scientific has extensive experience in clinical research and development, having supported numerous companies with custom-designed clinical trials over the past 23 years. The company is positioned as a leader in the mental health sector, leveraging state-of-the-art technologies and strategic partnerships to enhance treatment outcomes and expand its footprint in the industry. Generated from the website

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products ("DMT Products") for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.